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Available online 1 October 2015Autoimmune diseases (AIDs) consist of a group of physiolog-
ical disorders with highly diversified pathogenesis and clinical
manifestations [1], which affect more than 5% of the popula-
tion worldwide [2]. So far, the etiology of the AIDs is still
poorly understood, whereas it is generally believed that
autoimmune disorder results from a complex interaction of
genetic and epigenetic variations, as well as triggering environ-
mental factors [3]. Because of the varied phenotypes in differ-
ent individuals of one AID and sometimes shared
manifestations among patients with different AIDs, precise
diagnoses, prognosis, and effective treatment are hard to
achieve. In the last decade, with the explosion of multi-omics
technologies, such as genomics, transcriptomics, epigenetics,
proteomics, and metabolomics, the new high-throughput
approaches have been widely applied in the studies of
AIDs and led to the discovery of various biomarkers with
the potential to facilitate the precise medicine in a big data
paradigm.
In this special issue, we aimed to give an overview on the
most recent progress of biomarker studies on some of the
important autoimmune-related diseases, such as systemic lupus
erythematosus (SLE), psoriasis, systemic sclerosis (SSc), and
primary Sjogren’s syndrome (pSS). Dr. Tianfu Wu’s group
[4] provided a comprehensive review on the diagnosticbiomarkers of psoriasis, a chronic skin disease that affects
around more than 7.2 million people solely within the US in
2013 [5]. The biomarker discovery is especially essential for this
disease due to the heterogeneous therapeutic reactions among
individuals and the lack of cure, thus precise medicine might be
achieved through understanding of individuals’ immune
responses. The efforts of identifying suitable psoriasis
biomarkers have been continuously made using different meth-
ods, including conventional analyses and omics approaches
(genomics, transcriptomics, proteomics, and metabolomics),
with the fast-developing technologies as reviewed in this
paper.
The prevalence of pSS is hard to be estimated due to the
inconsistent classification criteria of the disease. It also varies
largely among surveys in different age groups, ethnicities,
and geographical regions with an obvious bias in female pop-
ulation [6]. Because of the phenotypic variances, diagnostic
biomarkers, especially non-invasive biomarkers, are valuable
for the early definitive diagnosis. Dr. Song-Guo Zheng’s group
[7] reviewed the recent progress of recruiting interferon type I
and Fms-like tyrosine kinase 3 ligand as the pSS biomarkers,
as well as the potential to find microRNA biomarkers using
genomics approaches.
SSc is a chronic multisystem AID with an estimated preva-
lence in the US to be around 240 cases/million adults [8]. With
the recent blooming of the microRNA studies, the epigenetic
effects on SSc have been extensively studied in the transform-
ing growth factor-b (TGF-b) pathway. Dr. Xiaoxiao Zuo’s
group [9] conducted an in-depth review specifically focused
on the epigenetic regulation on SSc and pointed out the
promising direction for new SSc biomarkers.
SLE is the prototypic AID predominately affecting woman
with the production of various autoantibodies as one of thences and
206 Genomics Proteomics Bioinformatics 13 (2015) 205–207major clinical manifestations. Proteomic microarray, as a
powerful high throughput autoantibody screening approach,
has been extensively utilized for identification of autoantibod-
ies associated with pathogenesis of SLE. A review from
Dr. Quan-Zhen Li’s group [10] discussed the most recent
progresses on the application of autoantigen microarrays for
profiling of autoantibodies in SLE and their potential
application as biomarkers for early diagnosis and therapeutic
intervention.
The review from Dr. Haitao Niu’s group [11], on the other
hand, focused on using next-generation sequencing (NGS)
technology to identify biomarkers for several AIDs, such as
SLE, SSc, and rheumatoid arthritis (RA). Other than the
review articles on various AIDs, Dr. Yigang Tong [12] also
highlighted a recently-published study on the altered micro-
biomes in RA patients, which could potentially serve as a
biomarker for disease diagnosis and treatment response [13].
Two original articles are included to enlarge the scope of this
special issue: Dr. Bruce Budowle [14] introduced their work
on short tandem repeat of Y-chromosome using the massively
parallel sequencing and Dr. Changqing Zeng’s group [15]
reported the genome-wide characteristics of esophageal
squamous cell carcinoma.
The multiple omics technologies have greatly facilitated the
discovery of biomarkers and improved our knowledge of the
etiopathology of AIDs. In the meantime, the advances in
high-throughput screening technologies offered excellent
opportunities to identify new biomarkers potentially useful
for early diagnosis, prognosis, and even prediction of thera-
peutic responses. Given the high complexities of the immune
system and diversification of AIDs, the exploration of novel
biomarkers and their underlying molecular mechanism will
continue to be hot topics in the study of AIDs. Putting these
articles together in this special issue might be helpful to reveal
the intercommunication of the AIDs in the new bioinformatics
and big data picture and may shed light on other less-studied
AIDs or the discovery of universal biomarkers. In addition,
novel biomarkers, especially the non-invasive biomarkers, are
greatly demanded. Methodologically, application of the
state-of-art novel technologies, such as NGS, as well as high-
throughput proteomics and metabolomics approaches, in com-
bination with various data analysis platforms, would greatly
facilitate the discovery of multiple disease biomarkers and
assessment of genes, proteins, metabolites, and network anal-
ysis of complex pathways implicated in the specific AID condi-
tions. Comprehensive understanding of the relationship
between the biomarkers and AIDs will not only provide valu-
able tools for disease prediction, early diagnosis, and progno-
sis, but also shed light on the identification of novel
therapeutic target for treatment of the diseases.
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